Clinical data have demonstrated effective HER2 targeting in patients with HER2-positive BC refractory to TZMB when treated with IPI-504 in combination with TZMB, with modest anti-tumor effects [137] (Table 1). The gene discussed is ERBB2; the disease is breast cancer.